Enough people asked me about Medvi, thought I'd share some stuff that I think is missing from the main narrative. Not mentioned in the article was there was a 2-3 year period where the FDA declared a shortage of weight loss drugs and compounded GLP1's were a DTC marketers dream -> unprecedented demand for a product where the alternative cost $1000-1500, was unavailable and you could sell the exact same chemical for $250. Most digital health companies were trying to build some lifetime value around the care model/patient experience to capture more margin & build equity value. A pure marketing-focused firm with no board or clinical team could move much faster. IE Medvi optimized for profits vs long term equity value - which basically worked Now, compounding is more highly regulated (new rules coming down this month) and the branded prices coming down to the $200-range, the arbitrage has been eroded. Medvi today has an issue - the company made $400m last year but the "special sauce" of being able to sell a highly discounted product has been diminished. By definition his CAC will be higher and Medvi already has thin margins. The founder probably wants some credit and releasing his numbers at the peak. He's now known as the "first vibe-coded" billionaire which is monetizable - I am sure he will leverage for new deals, financing, etc...
I wonder if they will go after him for deceptive marketing tactics like setting up fake Dr profiles, or use ai generated before and after photos. 🥱
Guy Friedman you forgot to add But this is not just a story about innovation. It is also a story about what happens when scale outruns accountability. Impersonating a doctor and creating fake doctor profiles to advertise and sponsor your company that sells compounded medical drugs is highly illegal. Full stop. Gallagher allegedly created more than 800 Facebook accounts posing as doctors to promote these products. That is not clever growth. That is fraud-adjacent behavior in a heavily regulated medical context. And the surrounding record makes the picture even worse. Medvi received FDA Warning Letter #721455 in February 2026 for misbranding violations. Its clinician network, OpenLoop, suffered a data breach in January 2026 that exposed 1.6 million patient records. Futurism reported the company used AI-generated deepfake before-and-after images in its marketing. A class action lawsuit was filed in Delaware in November 2025. So yes, this may look like the arrival of the AI-powered one-person unicorn. It also looks like a case study in what happens when synthetic media, regulatory arbitrage, and automated distribution move faster than ethics, compliance, and patient safety.
Short version: first street corner drug dealer to make $B off a website. Appreciate the analysis.
It feels like every few years there are these windfall opportunities in HC. Curative made a billion plus (I believe) on COVID tests for instance. And then the bottom drops out of the market. An interesting trend I haven’t seen in many other industries.
This is a great summary and signal.
NYT showing once again who it works for
Smart take
Well said. Fully agree!
Strong take from an expert in the space. One more I'd add, the "one employee" headline is attractive for clicks but there's a whole lot under the hood here in terms of outsourcing jobs to third parties. And I find the distinction between contractor + FTE quite arbitrary. e.g. 7 full time account managers, whether they are contractors or FTEs, is a customer success team.